NEW YORK (GenomeWeb) – Great Basin Scientific's board has approved a 1-for-300 reverse stock split, following approval by its shareholders, the company said on Thursday in a document filed with the US Securities and Exchange Commission.

The shareholder approval took place during a special meeting, during which shareholders approved a reverse stock split at a ratio of between 1 for 200 and 1 for 300. Subsequently, the board approved the split at the 1-for-300 ratio.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.